Peer-reviewed veterinary case report
MCL-1 protein levels linked to prognosis in dog mammary tumors
By Cho, Jaeho et al.·Published in PloS one·2024·Department of Veterinary Clinical Sciences, South Korea·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Evaluation of MCL-1 as a prognostic factor in canine mammary gland tumors.
- Species:
- dog
Plain-English summary
A study looked at the role of a protein called MCL-1 in dogs with mammary gland tumors, which can be benign or malignant. Researchers found that high levels of MCL-1 were present in 53% of benign tumors and 75% of malignant tumors, while only 8% of normal mammary glands showed high levels. Dogs with malignant tumors that had high MCL-1 levels tended to have larger tumors and a shorter survival time. This suggests that MCL-1 could be an important factor to consider when diagnosing and treating mammary tumors in dogs.
People also search for: dog mammary tumor prognosis · high MCL-1 in dog tumors · canine mammary cancer treatment options
Abstract
Myeloid cell leukemia-1 (MCL-1), which belongs to the anti-apoptotic B cell lymphoma-2 family protein, is overexpressed in various cancers and is associated with cell immortality, malignant transformation, chemoresistance, and poor prognosis in humans. However, the significance of MCL-1 in canine mammary gland tumors (MGTs) remains unknown. This study aimed to examine MCL-1 expression in normal canine mammary glands and tumors and to assess its correlation with clinical and histologic variables. In total, 111 samples were examined, including 12 normal mammary gland tissues, 51 benign MGTs, and 48 malignant MGTs. Immunohistochemistry revealed that 53% of benign tumors and 75% of malignant tumors exhibited high MCL-1 expression, whereas only 8% of normal mammary glands exhibited high MCL-1 expression. High MCL-1 expression correlated with tumor malignancy (p < 0.001), large tumor size (> 3 cm) (p = 0.005), high Ki-67 expression (p = 0.046), and metastasis (p = 0.027). Survival curve analysis of dogs with malignant MGTs demonstrated a significant association between high MCL-1 expression and shorter median overall survival (p = 0.027) and progression-free survival (p = 0.014). Our study identified MCL-1 as a prognostic factor and potential therapeutic target in canine MGTs.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/39012900/